+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2019

  • ID: 4901394
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 561 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AB Science SA
  • Bayer AG
  • Eli Lilly and Co
  • Horizon Therapeutics PLC
  • Merck KGaA
  • Novartis AG
  • MORE
Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2019, provides an overview of the Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline landscape.

Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 18, 18, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AB Science SA
  • Bayer AG
  • Eli Lilly and Co
  • Horizon Therapeutics PLC
  • Merck KGaA
  • Novartis AG
  • MORE
Introduction
Report Coverage
Gastrointestinal Stromal Tumor (GIST) - Overview
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development
AB Science SA
ABL Bio Inc
Advanced Accelerator Applications SA
Advenchen Laboratories LLC
Arog Pharmaceuticals Inc
ArQule Inc
Ascentage Pharma Group International
Bayer AG
Blueprint Medicines Corp
Calithera Biosciences Inc
Chipscreen Biosciences Ltd
CStone Pharmaceuticals Co Ltd
Daiichi Sankyo Co Ltd
Deciphera Pharmaceuticals Inc
Eli Lilly and Co
Esperas Pharma Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Hanmi Pharmaceuticals Co Ltd
Hefei Cosource Pharmaceutical Inc
Horizon Therapeutics PLC
Immunicum AB
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Karyopharm Therapeutics Inc
Marino Biotechnology Co Ltd
Merck & Co Inc
Merck KGaA
NantCell Inc
Natco Pharma Ltd
Ningbo Tai Kang Medical Technology Co Ltd
NMS Group SpA
Novartis AG
Omeros Corp
Pfizer Inc
Pharma Mar SA
Plexxikon Inc
Rhizen Pharmaceuticals SA
Sartar Therapeutics Ltd
Shanghai Haihe Biopharma Co Ltd
Shijiazhuang Yiling Pharmaceutical Co Ltd
SignalRx Pharmaceuticals Inc
Soricimed Biopharma Inc
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Xencor Inc
Gastrointestinal Stromal Tumor (GIST) - Drug Profiles
ABL-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aldoxorubicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products
Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H2 2019
Gastrointestinal Stromal Tumor (GIST) - Pipeline by ABL Bio Inc, H2 2019
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H2 2019
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H2 2019 (Contd..1), H2 2019
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AB Science SA
  • ABL Bio Inc
  • Advanced Accelerator Applications SA
  • Advenchen Laboratories LLC
  • Arog Pharmaceuticals Inc
  • ArQule Inc
  • Ascentage Pharma Group International
  • Bayer AG
  • Blueprint Medicines Corp
  • Calithera Biosciences Inc
  • Chipscreen Biosciences Ltd
  • CStone Pharmaceuticals Co Ltd
  • Daiichi Sankyo Co Ltd
  • Deciphera Pharmaceuticals Inc
  • Eli Lilly and Co
  • Esperas Pharma Inc
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Hefei Cosource Pharmaceutical Inc
  • Horizon Therapeutics PLC
  • Immunicum AB
  • Ipsen SA
  • Jiangsu Hengrui Medicine Co Ltd
  • Karyopharm Therapeutics Inc
  • Marino Biotechnology Co Ltd
  • Merck & Co Inc
  • Merck KGaA
  • NantCell Inc
  • Natco Pharma Ltd
  • Ningbo Tai Kang Medical Technology Co Ltd
  • NMS Group SpA
  • Novartis AG
  • Omeros Corp
  • Pfizer Inc
  • Pharma Mar SA
  • Plexxikon Inc
  • Rhizen Pharmaceuticals SA
  • Sartar Therapeutics Ltd
  • Shanghai Haihe Biopharma Co Ltd
  • Shijiazhuang Yiling Pharmaceutical Co Ltd
  • SignalRx Pharmaceuticals Inc
  • Soricimed Biopharma Inc
  • Taiho Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Xencor Inc
Note: Product cover images may vary from those shown
Adroll
adroll